INC Research Appoints Head of Metabolic & Endocrine Diseases Clinical Division
24 July 2008
INC Research, a therapeutically-focused contract research organization (CRO) with a process for delivering reliable results, today announced that David Subich, MD has been named the senior director, Clinical Operations for Metabolic and Endocrine diseases. Based in Raleigh, he will be overseeing existing related trials currently being conducted and developing comprehensive services for this growing therapeutic area.
Dr. Subich has 23 years of experience as an attending physician specialising in internal medicine with a focus on metabolic and endocrine diseases. His rich background includes starting his own practice group, North Central Ohio Clinic, serving as a hospitalist, and a role as medical director covering several area nursing homes. Since 1991, Dr. Subich was the principal investigator on more than 50 clinical trials, where he was responsible for staff and study oversight, patient exams and Good Clinical Practices (GCP) at the research site.
He also served as an associate professor for clinical rotations for The Ohio State University School of Medicine where he was recognized for his teaching excellence. He has frequently presented on scientific and educational panels on a range of treatment, practice and clinical issues related to metabolic and endocrine diseases. Dr. Subich was trained at The Cleveland Clinic Foundation after an internship at Baylor College of Medicine in Houston. He received his medical degree from The Medical College of Ohio.
“Dr. Subich has a unique combination of research experience and hands-on medical practice in a variety of environments. He has witnessed the rise of metabolic diseases as a physician and understands the benefits of developing safe and effective drugs to treat patients,” said John Potthoff, COO of INC Research. “Our trusted process methodology gives us the framework to efficiently expand into new therapeutic areas as drug development trends emerge. We are thrilled Dr. Subich has joined our team to establish our Metabolic and Endocrine division.”
“Diabetes and obesity are among the more prevalent metabolic disorders, and we are seeing those greatly increase on a global basis,” said Dr. Subich. “I am excited to leverage the knowledge inside of INC Research to build a world-class team to address the unmet clinical needs for pharmaceutical and biotech companies, exploring current and future targets for metabolic and endocrine diseases.”
